首页 / 院系成果 / 成果详情页

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial 期刊论文

编号：

b20529ec-2943-455e-b0a2-407c7bfddf88
作者：

Xiao, Shifu(肖世富)#^[1,2]Wang, Tao(王涛)^[1,2]Ma, Xiuqiang^[3];Qin, Yingyi^[3];Li, Xia(李霞)^[1]Zhao, Zhongxin(赵忠新)^[4]Liu, Xueyuan(刘学源)^[5]Wang, Xiaoping(王晓平)^[6]Xie, Hengge(解恒革)^[7]Jiang, Qinpu^[8];Sun, Li(孙莉)^[9]Luo, Benyan(罗本燕)^[10]Shang, Lan(尚兰)^[11]Chen, Weixian(陈伟贤)^[12]Bai, Yan(白燕)^[13]Tang, Muni^[14];He, Maolin(贺茂林)^[15]Wu, Lan^[16];Ma, Qilin^[17];Hou, Deren(侯德仁)^[18]He, Jia(贺佳)*^[3]
语种：

英文
期刊：

AGE AND AGEING ISSN：0002-0729 2017 年 46 卷 5 期 (767 - 773) ; SEP
收录：
关键词：

older people octohydroaminoacridine Alzheimer's disease treatment novel drug Phase II trial
摘要：

Background: inhibition of acetylcholinesterase (AChE) has been a effective treatment for Alzheimer's disease (AD). Octohydroaminoacridine, a new AChE inhibitor, is a potential treatment for AD.
Method: we conducted a multicenter, randomised, double blind, placebo-controlled, parallel-group Phase II clinical trial to investigate the effects of octohydroaminoacridine in patients with mild-to-moderate AD. Patients were randomised to receive placebo thrice daily, octohydroaminoacridine 1 mg/thrice daily (TID) (low-dose group), 2 mg/TID (middle-dose group) or 4 mg/TID (high-dose group). Doses in the middle-dose and high-dose group were titrated over 2-4 weeks. Changes from baseline to Week 16 were assessed with the AD Assessment Scale-Cognitive Subscale (ADAS-cog), Clinician's Interview-Based Impression of Change Plus (CIBIC+), activities of daily living (ADL) and the neuropsychiatric inventory (NPI). ADAS-cog was the primary end point of the study. A two-way analysis of covariance and least squares mean t-test were used.
Results: at Week 16, the changes from baseline in ADAS-cog were 1.4, -2.1, -2.2 and -4.2 for placebo, low-, middle-and high-dose groups, respectively. Patients in the high-dose group had better performance in CIBIC+ and ADL scores at the end of the study. There was no significant difference in the change in NPI score among the groups. The effects of octohydroaminoacridine were dose dependent, and were effective within 16 weeks of treatment. No evidence was found for more adverse events that occurred in different drug groups than placebo group.
Conclusions: octohydroaminoacridine significantly improved cognitive function and behaviour in patients with mild-to-moderate AD and this effect was dose dependent.
推荐引用方式
GB/T 7714：

Xiao Shifu,Wang Tao,Ma Xiuqiang, et al. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial [J].AGE AND AGEING,2017,46(5):767-773.
APA：

Xiao Shifu,Wang Tao,Ma Xiuqiang,Qin Yingyi,&He Jia.(2017).Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial .AGE AND AGEING,46(5):767-773.
MLA：

Xiao Shifu, et al. "Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial" .AGE AND AGEING 46,5(2017):767-773.
入库时间：

2020/4/13 14:43:52
更新时间：

2020/4/13 14:43:52
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：130  下载次数：0

分享到：

浏览次数：130

下载次数：0

打印次数：0